secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139506
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia receives Nasdaq delisting notice for bid price non-compliance; plans appeal
--------------------------------------------------------------------------------

- Notified May 9, 2023 for failing minimum bid price (Rule 5550(a)(2)) after second 180-day grace period expired May 8, 2023.
- Company will request a hearing before Nasdaq Hearings Panel, which stays delisting pending panel decision.
- If delisted, expects common stock to be eligible for trading on OTC Markets platform.
- Previous grace periods granted May 2022 and Nov 2022; company did not regain compliance by May 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523139506/0001193125-23-139506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523139506/d471133d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer